Navigation Links
SARcode Bioscience Completes $44 Million Series B Financing
Date:7/18/2011

BRISBANE, Calif., July 18, 2011 /PRNewswire/ -- SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today the completion of a $44 million Series B private equity financing.  The financing round was led by Sofinnova Ventures and was augmented by the additional backing of Rho Ventures and existing investors Alta Partners and Clarus Venture Partners.

(Logo: http://photos.prnewswire.com/prnh/20110718/FL36481LOGO)

"We believe that SARcode is uniquely positioned to make significant breakthroughs in the treatment of dry eye that could improve therapeutic options for millions of patients," commented Garheng Kong, General Partner of Sofinnova Ventures.  "SARcode's proprietary compound has demonstrated the ability to alleviate both the signs and symptoms of dry eye by directly targeting the inflammatory origin of this debilitating disease," Kong added.  "We have been impressed by the broad ophthalmic product development and marketing experience of the SARcode executive team and look forward to working with them and the investor syndicate as the company's lead dry eye program moves into Phase 3 clinical trials," said Martin Vogelbaum, Partner at Rho Ventures.

Proceeds from the Series B financing will largely support further clinical development of SAR 1118, SARcode's lead compound for the treatment of dry eye syndrome.  SAR 1118 is a first-in-class, topical small-molecule integrin antagonist that inhibits T-cell mediated inflammation, a key component of dry eye.  In a Phase 2 randomized, placebo-controlled trial of 230 subjects with dry eye disease, SAR 1118 demonstrated an improvement in corneal staining at 12 weeks and an increase in tear production as early as 2 weeks.  In addition, subjects receiving SAR 1118 reported dose-dependent improvements in visual-related function at 12 weeks, which included the ability to read, drive at night, use a computer and watch television.  SAR 1118 was
'/>"/>

SOURCE SARcode Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
2. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
3. Quinton Oswald Named Chief Executive Officer of SARcode Corporation
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , Sept. 30, 2014  Hologic, Inc. (NASDAQ: ... , Hologic,s President and Chief Executive Officer, will preside ... October 1, the first day of Breast Cancer Awareness ... Company,s campaign focused on the important benefits of Hologic,s ... the FDA as clinically superior to traditional mammography. ...
(Date:9/30/2014)... , Sept. 30, 2014 Arbor ... Summary Global Markets Direct,s, ,Arbor Pharmaceuticals, ... an overview of the Arbor Pharmaceuticals, LLC.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... September 30, 2014 ... the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, ... and Reagents], Application (Immunology, Oncology) & by ... published by MarketsandMarkets, provides a detailed overview ... current market trends, and strategies impacting the ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
... 26, 2011 NuMe Health LLC, a biotechnology company ... today announced that it has closed a series A-1 ... chief executive officer.  The $675,000 financing was led by ... a larger series A round. The funds from the ...
... 2011 Reportlinker.com announces that a new ... catalogue: China Cardiac Catheters ... http://www.reportlinker.com/p0575380/China-Cardiac-Catheters-and-Guidewires---Market-Trends-Till-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment ... This market report provides vital market data ...
Cached Medicine Technology:NuMe Health Announces Closing of Series A-1 Financing Round 2NuMe Health Announces Closing of Series A-1 Financing Round 3NuMe Health Announces Closing of Series A-1 Financing Round 4NuMe Health Announces Closing of Series A-1 Financing Round 5China Cardiac Catheters and Guidewires - Market Trends Till 2016 2China Cardiac Catheters and Guidewires - Market Trends Till 2016 3
(Date:10/1/2014)... ST. LOUIS, MO (PRWEB) October 01, 2014 ... up for Castlewood Eating Disorder Treatment Center’s first ever charity ... provides grants for people with eating disorders who cannot afford ... Fox Run Golf Club in Eureka, Mo. , The ... time at noon. A reception and award dinner will begin ...
(Date:10/1/2014)... 01, 2014 Beverly Hills licensed Clinical ... is celebrating 20 years of private practice in her ... people to achieve greater joy and fulfillment in their ... warning signs and suggestions for anyone who suspects they ... “Believe it or not, it’s not always easy ...
(Date:10/1/2014)... Innovations announces the upcoming airing of Innovations with ... 20, 2014 at 7:30 a.m. EST/PT via Discovery Channel. ... scenes to learn about Break the Cycle’s comprehensive dating ... help and information Break the Cycle provides to teens ... abuse, how to navigate the legal system, and provides ...
(Date:10/1/2014)... NoteSwift Inc., announced today their new ... and 13.0. NoteSwift is the bridge between the EHR ... and document clinical information at the point of care. ... patient note by more than half – and virtually ... points providers state impedes EHR use according to the ...
(Date:10/1/2014)... Scientists at the University of Western ... immune system proteins has the power to knock out ... of the new study on their website. Click ... in the UWA School of Pathology and Laboratory Medicine ... with mesothelioma with promising results. , “A timed ...
Breaking Medicine News(10 mins):Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 2Health News:Prominent Beverly Hills Psychologist Dr. Kathleen Mojas Celebrating 20 Years in Private Practice Identifies Common Warning Signs That You May Be In a Toxic Relationship. 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2Health News:NoteSwift Joins Allscripts Developer Program 2Health News:NoteSwift Joins Allscripts Developer Program 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2
... 5, 2008--Worldwide, an average 95.4 percent of LASIK patients ... first review of the world body of scientific literature, ... announced today. , With 16.3 million patients having ... clinical study and technological innovation behind it, LASIK is ...
... March 7 The rheumatoid arthritis (RA),treatment market, held ... withdrawal of Vioxx and Bextra, is rebounding due to ... to,treat RA topped $12 billion in 2006 and -- ... over 11% a year through 2011,according to a new ...
... Following Bi-Partisan Senate Letter, asks Lawmakers,to Reject Proposed ... Make,Reform Much More Difficult to Achieve, Letter ... WASHINGTON, March 7 The Council for Quality,Respiratory ... leading home oxygen,therapy providers and manufacturers who provide ...
... chief of developmental neurobiology at the Medical College of ... has received the 2008 Mathilde Solowey Lecture Award in ... for Advanced Education in the Sciences, honors young or ... edge, translational and of broad importance. , Dr. Mei ...
... generated by ... physicians in SEMI program, DETROIT, March 7 ... 2.5 million electronic prescriptions written in,the state of Michigan in 2007 ... Initiative (SEMI) -- helping drive,Michigan to fifth in the nation in ...
... Corgenix Medical Corporation,(OTC Bulletin Board: CONX), a ... be exhibiting its AspirinWorks(R) Test at the,American College ... 2008 conference is being held March 12-14 at ... will be on-hand at booth #807 during ACOFP ...
Cached Medicine News:Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 2Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 3Health News:LASIK patients report more than 95 percent satisfaction rate worldwide 4Health News:In Post-Vioxx Era, Biologics are Reviving the Arthritis Treatment Market 2Health News:Bi-Partisan Members of U.S. House of Representatives Formally Oppose Funding Reductions to Medicare's Home Oxygen Benefit 2Health News:Bi-Partisan Members of U.S. House of Representatives Formally Oppose Funding Reductions to Medicare's Home Oxygen Benefit 3Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 2Health News:Dr. Mei receives 2008 Mathilde Solowey Lecture Award in Neurosciences 3Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 2Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 3Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 4Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 5Health News:Southeast Michigan ePrescribing Initiative (SEMI) Drives Michigan into Top Five ePrescribing States Nationally 6Health News:Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver 2Health News:Corgenix to Exhibit AspirinWorks(R) Test at 2008 ACOFP Meeting in Denver 3
... Laparoscopic Instruments incorporate a layered design unique ... and monitored to prevent stray electrosurgical burns ... by insulation failure or capacitive coupling; a ... built into all AEM Instruments provides a ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
Medicine Products: